The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients

Jing Houng Wang; Chi Sin Changchien; Tsung Hui Hu; Chuan Mo Lee; Kwong Ming Kee; Chih Yun Lin; Chao Long Chen; Tai Yi Chen; Yu Jie Huang; Sheng Nan Lu

doi:10.1016/j.ejca.2008.02.018

The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients

Jing Houng Wang, Chi Sin Changchien, Tsung Hui Hu, Chuan Mo Lee, Kwong Ming Kee, Chih Yun Lin, Chao Long Chen, Tai Yi Chen, Yu Jie Huang, Sheng Nan Lu^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal Article › peer-review

184 Scopus citations

Abstract

The Barcelona Clinic Liver Cancer (BCLC) staging offers prognostic stratification and treatment allocation for hepatocellular carcinoma (HCC). We conducted this retrospective study to assess the efficacy of different treatment options for patients with initial HCC diagnosis. Survival rate and median survival times associated with different treatment options in each stage of BCLC classification were compared using the Kaplan-Meier method and log-rank test. A total of 3892 patients were enrolled. Overall survival rates were 46.2% at 1 year and 16.6% at 5 years. The median survival times decreased from 57.7 months in very early stage to 1.6 months in terminal stage. Surgical resection offered the best survival benefit for patients in very early, early and even intermediate stages. Transarterial embolisation and conformal radiotherapy offered survival benefits for selected patients in advanced and terminal stages. In conclusion, following the treatment schedules allocated by BCLC staging had survival benefits for HCC patients.

Original language	English
Pages (from-to)	1000-1006
Number of pages	7
Journal	European Journal of Cancer
Volume	44
Issue number	7
DOIs	https://doi.org/10.1016/j.ejca.2008.02.018
State	Published - 05 2008
Externally published	Yes

Keywords

Barcelona Clinic Liver Cancer (BCLC) staging
Hepatocellular carcinoma
Survival analysis
Treatment options

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ejca.2008.02.018

Cite this

Wang, J. H., Changchien, C. S., Hu, T. H., Lee, C. M., Kee, K. M., Lin, C. Y., Chen, C. L., Chen, T. Y., Huang, Y. J., & Lu, S. N. (2008). The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients. European Journal of Cancer, 44(7), 1000-1006. https://doi.org/10.1016/j.ejca.2008.02.018

@article{379fcb3461e34547917e304153678a76,

title = "The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients",

abstract = "The Barcelona Clinic Liver Cancer (BCLC) staging offers prognostic stratification and treatment allocation for hepatocellular carcinoma (HCC). We conducted this retrospective study to assess the efficacy of different treatment options for patients with initial HCC diagnosis. Survival rate and median survival times associated with different treatment options in each stage of BCLC classification were compared using the Kaplan-Meier method and log-rank test. A total of 3892 patients were enrolled. Overall survival rates were 46.2% at 1 year and 16.6% at 5 years. The median survival times decreased from 57.7 months in very early stage to 1.6 months in terminal stage. Surgical resection offered the best survival benefit for patients in very early, early and even intermediate stages. Transarterial embolisation and conformal radiotherapy offered survival benefits for selected patients in advanced and terminal stages. In conclusion, following the treatment schedules allocated by BCLC staging had survival benefits for HCC patients.",

keywords = "Barcelona Clinic Liver Cancer (BCLC) staging, Hepatocellular carcinoma, Survival analysis, Treatment options",

author = "Wang, {Jing Houng} and Changchien, {Chi Sin} and Hu, {Tsung Hui} and Lee, {Chuan Mo} and Kee, {Kwong Ming} and Lin, {Chih Yun} and Chen, {Chao Long} and Chen, {Tai Yi} and Huang, {Yu Jie} and Lu, {Sheng Nan}",

year = "2008",

month = may,

doi = "10.1016/j.ejca.2008.02.018",

language = "英语",

volume = "44",

pages = "1000--1006",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd",

number = "7",

}

TY - JOUR

T1 - The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients

AU - Wang, Jing Houng

AU - Changchien, Chi Sin

AU - Hu, Tsung Hui

AU - Lee, Chuan Mo

AU - Kee, Kwong Ming

AU - Lin, Chih Yun

AU - Chen, Chao Long

AU - Chen, Tai Yi

AU - Huang, Yu Jie

AU - Lu, Sheng Nan

PY - 2008/5

Y1 - 2008/5

N2 - The Barcelona Clinic Liver Cancer (BCLC) staging offers prognostic stratification and treatment allocation for hepatocellular carcinoma (HCC). We conducted this retrospective study to assess the efficacy of different treatment options for patients with initial HCC diagnosis. Survival rate and median survival times associated with different treatment options in each stage of BCLC classification were compared using the Kaplan-Meier method and log-rank test. A total of 3892 patients were enrolled. Overall survival rates were 46.2% at 1 year and 16.6% at 5 years. The median survival times decreased from 57.7 months in very early stage to 1.6 months in terminal stage. Surgical resection offered the best survival benefit for patients in very early, early and even intermediate stages. Transarterial embolisation and conformal radiotherapy offered survival benefits for selected patients in advanced and terminal stages. In conclusion, following the treatment schedules allocated by BCLC staging had survival benefits for HCC patients.

AB - The Barcelona Clinic Liver Cancer (BCLC) staging offers prognostic stratification and treatment allocation for hepatocellular carcinoma (HCC). We conducted this retrospective study to assess the efficacy of different treatment options for patients with initial HCC diagnosis. Survival rate and median survival times associated with different treatment options in each stage of BCLC classification were compared using the Kaplan-Meier method and log-rank test. A total of 3892 patients were enrolled. Overall survival rates were 46.2% at 1 year and 16.6% at 5 years. The median survival times decreased from 57.7 months in very early stage to 1.6 months in terminal stage. Surgical resection offered the best survival benefit for patients in very early, early and even intermediate stages. Transarterial embolisation and conformal radiotherapy offered survival benefits for selected patients in advanced and terminal stages. In conclusion, following the treatment schedules allocated by BCLC staging had survival benefits for HCC patients.

KW - Barcelona Clinic Liver Cancer (BCLC) staging

KW - Hepatocellular carcinoma

KW - Survival analysis

KW - Treatment options

UR - http://www.scopus.com/inward/record.url?scp=42649135205&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2008.02.018

DO - 10.1016/j.ejca.2008.02.018

M3 - 文章

C2 - 18337087

AN - SCOPUS:42649135205

SN - 0959-8049

VL - 44

SP - 1000

EP - 1006

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 7

ER -

The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this